arznei-telegramm Logo a-t Kurzlogo
    ❮ a-t 3/2024 a-t ❯
    This is a translation of the table of contents. One article of each issue is translated and freely available.
    table of contents
    SPOT ON

    Medical conditions of unclear origin: can these be triggered by a medication?

    NEW ON THE MARKET

    Lebrikizumab (EBGLYSS) for the treatment of atopic dermatitis

    Hexamidine eye drops (ZAMIDINE) against conjunctivitis and blepharitis?

    THERAPY FROM A CRITICAL VIEWPOINT

    Smoking cessation: varenicline and nicotine replacement with added benefit

    IN BRIEF

    Flu vaccines: WHO recommends trivalent vaccines

    Thromboembolic risk of chlormadinone-containing contraceptives (e.g. BELARA) and of the long cycle contraceptive SEASONIC is in the midfield range

    Delivery failure of sodium perchlorate (IRENAT) results in additional costs of several million euros

    Overall survival shortened – approval of melphalan flufenamide (PEPAXTI) revoked in the USA, but not in the EU

    SIDE EFFECTS

    Respiratory syncytial virus vaccines ABRYSVO and AREXVY: possible risk of Guillain-Barré syndrome?
    free

    Isotretinoine: prescriptions for young women are increasing

    News on the safety of testosterone (e.g. TESTOGEL)

    arznei-telegramm

    Independent drug information – in English

    Concise, critical evaluations of drugs and medical devices for evidence-based therapy and patient advice on benefits and risks – independent, ad-free and funded exclusively by subscriptions.

    Browse free articles

    Wir schätzen Ihr Feedback

    Nehmen Sie an unserer Umfrage teil!